Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Leases (2019 - 2025)

Autolus Therapeutics (AUTL) has disclosed Current Leases for 7 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases rose 35.31% year-over-year to $4.8 million, compared with a TTM value of $4.8 million through Sep 2025, up 35.31%, and an annual FY2024 reading of $3.0 million, down 40.67% over the prior year.
  • Current Leases was $4.8 million for Q3 2025 at Autolus Therapeutics, up from $3.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $6.2 million in Q2 2023 and bottomed at $3.0 million in Q1 2025.
  • Average Current Leases over 5 years is $4.4 million, with a median of $4.5 million recorded in 2021.
  • The sharpest move saw Current Leases surged 55.97% in 2023, then tumbled 40.67% in 2024.
  • Year by year, Current Leases stood at $4.5 million in 2021, then increased by 13.14% to $5.0 million in 2022, then increased by 0.3% to $5.1 million in 2023, then crashed by 40.67% to $3.0 million in 2024, then surged by 61.04% to $4.8 million in 2025.
  • Business Quant data shows Current Leases for AUTL at $4.8 million in Q3 2025, $3.3 million in Q2 2025, and $3.0 million in Q1 2025.